Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2022-09-05
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-07 (study day 15); relationship: N
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 17); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 48); relationship: N
mild
assessed
2026-08-18
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 81); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 87); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.